Valsartan |
Diovan |
Article: Valsartan
| Image:Valsartan.png | |
| Valsartan | |
| Systematic (IUPAC) name | |
| 3-methyl-2- [pentanoyl-[ [4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl]amino] -butanoic acid | |
| Identifiers | |
| CAS number | 137862-53-4 |
| ATC code | C09CA03 |
| PubChem | 60846 |
| DrugBank | APRD00133 |
| Chemical data | |
| Formula | C24H29N5O3 |
| Mol. weight | 435.519 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 95% |
| Metabolism | ? |
| Half life | 6 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | D |
| Legal status | ℞ Prescription only |
| Routes | oral |
Valsartan (Diovan®) is an angiotensin II receptor antagonist, acting on the AT1 subtype. It is used to treat high blood pressure, congestive heart failure, and may be used to treat chronic renal failure.
Administration
Oral tablets, containing 20 mg, 40 mg, 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40-320 mg daily. Diovan HCT® contains a combination of valsartan and hydrochlorothiazide.
Side effects
Most commonly, headache and dizziness.
- More information in PubMed for Valsartan
Categories: Pharmacology stubs | Angiotensin II receptor antagonists | Novartis

Not Signed In -


